Telix Pharmaceuticals’ (TLX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Telix Pharmaceuticals (NASDAQ:TLX) in a research report sent to investors on Tuesday,Benzinga reports. The brokerage currently has a $20.00 target price on the stock.

Other analysts also recently issued reports about the company. Wedbush restated an “outperform” rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. Finally, Royal Bank Of Canada lowered shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Telix Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.40.

Telix Pharmaceuticals Stock Performance

Shares of NASDAQ:TLX opened at $12.51 on Tuesday. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16. The business’s fifty day moving average price is $11.27 and its two-hundred day moving average price is $10.31. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $13.11.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Hennion & Walsh Asset Management Inc. purchased a new stake in Telix Pharmaceuticals in the second quarter valued at approximately $1,731,000. Private Advisor Group LLC increased its position in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after purchasing an additional 128,070 shares during the last quarter. XY Capital Ltd raised its stake in Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after purchasing an additional 58,739 shares during the period. Lazard Asset Management LLC raised its stake in Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after purchasing an additional 39,400 shares during the period. Finally, Bank of America Corp DE boosted its holdings in shares of Telix Pharmaceuticals by 523.8% in the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares during the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.